46 citations
,
February 2012 in “Oncology Reports” Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.
Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.
15 citations
,
December 2014 in “Dermatology and therapy” Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
4 citations
,
January 2024 in “Scientific Reports” Interferon therapy improves quality of life for chronic hepatitis B patients.
13 citations
,
June 2008 in “International Journal of Dermatology” Sorafenib can cause a unique skin reaction.
42 citations
,
April 2021 in “Pharmaceuticals” Five FDA-approved drugs may help block COVID-19 virus entry.
January 2011 in “Annals of dermatology/Annals of Dermatology” A woman's psoriasis improved after hepatitis C treatment with interferon, despite interferon's risk of worsening skin conditions.
36 citations
,
January 1993 in “Gut” High-dose interferon is effective for chronic hepatitis C but often causes flu-like symptoms.
14 citations
,
August 2017 in “International Journal of Immunopathology and Pharmacology” Photodynamic therapy improved skin issues from sorafenib when other treatments failed.
16 citations
,
January 2017 in “Archives of Medical Science” Sorafenib after liver surgery may increase survival for some liver cancer patients.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
45 citations
,
January 2007 in “Journal of Clinical Oncology” Sorafenib may cause hand-foot and stump syndrome, requiring early detection and management.
The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
October 2023 in “Journal of cystic fibrosis” 7 citations
,
March 2002 in “AIDS” Indinavir, especially with vitamin A, may cause bone changes, but switching to nelfinavir can reduce these effects.
9 citations
,
November 2012 in “Hepatology Research” A man lost all his hair permanently after hepatitis C treatment, a side effect not seen before.
28 citations
,
December 2001 in “European Journal of Pharmacology” M50054 may help treat hepatitis and hair loss from chemotherapy.
2 citations
,
January 2007 in “Acta Dermato Venereologica” A patient developed a blister at the injection site after hepatitis C treatment.
32 citations
,
October 2004 in “Pharmacotherapy” Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
41 citations
,
December 2008 in “Journal of the American Academy of Dermatology” Oral valganciclovir improved a patient's skin condition caused by immunosuppression.
11 citations
,
August 1988 in “PubMed” Interferon therapy is a promising and safe treatment for hepatitis B in Southeast Asia.
Low-dose sorafenib can cause severe facial acne, treatable with topical medication.
17 citations
,
January 1993 in “Journal of Gastroenterology and Hepatology” Interferon α‐2b can temporarily reduce hepatitis C virus and normalize liver enzyme levels.
13 citations
,
September 2022 in “International Journal of Molecular Sciences” Five existing drugs may help fight Swine Acute Diarrhea Syndrome Coronavirus.
32 citations
,
July 2017 in “Oncotarget” Alternating treatment with two drugs could help cells in a rapid aging disease.
22 citations
,
March 2017 in “Transplant Infectious Disease” Leflunomide successfully treated a rare skin condition in a liver transplant patient.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
November 2025 in “Journal of Investigative Dermatology” May 2023 in “Reactions Weekly”